Clinical Research Directory

Inclusion Criteria: * Patient must be ≥ 18 and ≤ 59 years of age * Patient must be assigned to this protocol by the MYELOMATCH Protocol * Patient must have newly diagnosed acute myeloid leukemia (AML) with FLT3 ITD mutation as assessed by central myeloMATCH testing with variant allele frequency (VAF) over 5% * Patient must not have any contraindications to the conventional chemotherapy used in this study * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Patient must not have Core-binding factor \[inv(16), t(16;16) or t(8;21)\] leukemia * Patient must not have acute promyelocytic leukemia * Patient must not have had prior therapy with deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) for myelodysplastic syndrome (MDS) * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for: * 7 months after the last dose of quizartinib for patients of childbearing potential and for 4 months after the last dose of quizartinib for patients who are able to father children * 6 months after the last dose of daunorubicin for all patients * 30 days after the last dose of venetoclax for patients of childbearing potential * 6 months after the last dose of azacitidine for patients of childbearing potential and for 4 months after the last dose of azacitidine for patients who are able to father children In addition, patient must not breastfeed during treatment and for 1 month after treatment ends * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible * Total bilirubin ≤ 2 x institutional upper limit of normal (ULN). Patients with Gilbert's Syndrome must have total bilirubin ≤ 3 x institutional ULN (labs must be obtained ≤ 7 days prior to protocol randomization) * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3.0 × institutional ULN (labs must be obtained ≤ 7 days prior to protocol randomization) * Creatinine Clearance (CrCL) ≥ 30 mL/min calculated using the Cockcroft-Gault equation (labs must be obtained ≤ 7 days prior to protocol randomization) * Left ventricular ejection fraction \> 45% (which must be obtained ≤ 2 weeks prior to randomization) * NOTE: Since quizartinib can increase corrected QT interval (QTc) and many patients will require supportive care agents that affect QTc, a baseline electrocardiogram (ECG) ≤ 2 weeks prior to randomization is recommended if clinically indicated * Patient must not have Common Terminology Criteria for Adverse Events (CTCAE) \> grade 3 hypokalemia, hypomagnesemia, or hypocalcemia. Patients with grade 1-2 electrolyte abnormalities are eligible while electrolytes are being corrected * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients must not have had history of treatment with cardiotoxic agents unless total anthracycline lifetime dose is \< 450 mg/m\^2 doxorubicin equivalents * Patients must not have uncontrolled or significant cardiovascular disease, including any of the following: * Fridericia's formula-corrected QT (QTcF) interval \> 450 ms; * Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome); * Systemic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg; * History of clinically relevant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes); * History of second (Mobitz II) or third degree heart block (patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker); * History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to randomization; * History of New York Heart Association class 3 or 4 heart failure; * Complete left bundle branch block * Patient must not require treatment with concomitant strong or moderate CYP3A4 inducers * Patient must not require treatment with concomitant strong CYP3A4 inhibitors (e.g., antifungal azoles) unless considered necessary for the prevention or treatment of infections - in which a quizartinib dose reduction will be required * Patient must not have any known gastrointestinal (GI) disease or prior GI procedure that could interfere with the oral absorption or tolerance of quizartinib or venetoclax, including difficulty swallowing * Patient must not have any uncontrolled intercurrent illness or any other significant condition(s) that would make this protocol unreasonably hazardous